Skip to main content
Premium Trial:

Request an Annual Quote

PacBio Raises IPO Target Again, to $244.4M

Premium

This article was originally published Oct. 21.

Pacific Biosciences has raised its maximum aggregate offering price for its planned initial public offering from $230 million to $244.4 million, according to an updated prospectus filed with the Securities and Exchange Commission last week.

The company now plans to register 14.375 million shares of common stock, to be sold for between $15 and $17 per share.

This is the second time this month that PacBio, which filed for its IPO in August (IS 8/24/2010), has raised its offering target. Earlier this month, the company increased the maximum aggregate offering price from $200 million to $230 million (IS 10/5/2010).

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.